CELL SIGNALLING AND CANCER TREATMENT

Sponsored by:
American Association for Cancer Research
European Organisation for Research and Treatment of Cancer
(Pharmacokinetics and Metabolism Group)
British Association for Cancer Research

December 5-9, 1993
El San Juan Hotel, San Juan, Puerto Rico

CONFERENCE CHAIRPERSONS
Garth Powis / Tucson, AZ
Paul Workman / Macclesfield, England

PROGRAM COMMITTEE
Sara A. Courtneidge / Heidelberg, Germany
Hans H. Grunicke / Innsbruck, Austria
John A. Hickman / Manchester, England
Katherine A. Kennedy / Washington, DC
John S. Lazo / Pittsburgh, PA
Thomas R. Tritton / Burlington, VT

SCIENTIFIC PROGRAM

Introduction
Garth Powis / Tucson, AZ
Allen I. Oliff / West Point, PA

Tyrosine Kinases and Inhibitors
Lewis T. Williams / San Francisco, CA
Alexander Levitzki / Jerusalem, Israel
Alex Matter / Basel, Switzerland

Serine/Threonine Kinases and Inhibitors
Peter J. Parker / London, England
Hans H. Grunicke / Innsbruck, Austria

GTP Binding Proteins
Alan K. Hall / London, England
Frank McCormick / Richmond, CA
Jay Gibbs / West Point, PA

Domain Binding and Inhibition
Sara A. Courtneidge / Heidelberg, Germany

Lipid Signalling
Lewis C. Cantley / Boston, MA
Alan P. Kozikowski / Rochester, MN
Paul Workman / Macclesfield, England
Garth Powis / Tucson, AZ

Modulation of Signalling in Combination Chemotherapy
Thomas R. Tritton / Burlington, VT
John S. Lazo / Pittsburgh, PA
Stephen B. Howell / La Jolla, CA

Signalling and the Cell Cycle
Laurent Meijer / Roscoff, France
Caroline Dive / Manchester, England
Michael J. Morin / Groton, CT
Doris L. Slate / Palo Alto, CA
Adrian L. Harris / Oxford, England

Gene Targeting
Stanley T. Crooke / Carlsbad, CA
Michael E. Hogan / Houston, TX

Summary
Paul Workman / Macclesfield, England

Applicants are encouraged to submit abstracts for poster presentation.

Information and Application Forms
American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)

Application Deadline: September 7, 1993
After completing medical school at Ohio State in 1947, and performing his internship and residencies in Cleveland and Boston, in 1953 Dr. Krakoff joined the Memorial-Sloan Kettering group, directed by Drs. Joseph Burchenal and David Karnofsky. In 1970, his broad involvement in the drug development program led to his appointment as Chief of the Medical Oncology Service of Memorial Hospital and Chief of the Division of Chemotherapy of the Sloan-Kettering Institute, New York, NY (right), reflecting his dual commitment to laboratory and clinical investigation. In 1976, he became Director of the Vermont Regional Cancer Center, Burlington, VT (left). Under his leadership, this center became a regional resource for coordinating the care of cancer patients between oncologists and local physicians.

In 1983, Dr. Krakoff became Head of the Division of Medicine at the University of Texas M. D. Anderson Cancer Center, Houston, TX (top center). During the ten years of his stewardship, the medical program at M. D. Anderson doubled its clinical faculty and markedly expanded its laboratory programs in pharmacology, chemistry, immunology, chemoprevention, and molecular biology. Today, the Division has nearly 200 physician and scientist faculty members and is responsible for the treatment of close to 6000 new patients each year. Its research programs include over 400 active clinical trials, which are supported by more than 20 million dollars of grant and contract funding. These programs are respected for the rigorous data management and reporting systems initiated under Dr. Krakoff’s leadership.

However, Dr. Krakoff’s most important contributions to the future of cancer therapy and research have been in the area of education. In his role as director of three major oncology programs, Dr. Krakoff not only helped to establish the foundation of the new science but also dedicated himself to the training of the second and third generations of clinical investigators, who are continuing the rigorous trials which lead to further advances in drug therapy. His precept that learning whether a chemotherapy agent is effective is not as important as determining why it is effective has shaped the thinking of hundreds of medical oncology researchers. The field of medical oncology has benefitted immensely from this imprint.

We are indebted to Dr. Waun Ki Hong and the M. D. Anderson Cancer Center staff for providing the photographs and background information.

Sidney Weinhouse